Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 3/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.35 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12477574 | 1.00 | AR (0.39) | ARRIPK1GPR119EPAS1GRM5 | |
| SCHEMBL17067861 | 0.83 | RIPK1 (0.46) | RIPK1GPR119 | |
| SCHEMBL469821 | 0.83 | RIPK1 (0.46) | RIPK1GPR119 | |
| SCHEMBL445752 | 0.81 | AR (0.40) | ARRIPK1GPR119EPAS1 | |
| SCHEMBL12688003 | 0.81 | AR (0.40) | ARRIPK1GPR119EPAS1 | |
| SCHEMBL445864 | 0.81 | AR (0.40) | ARRIPK1GPR119EPAS1 | |
| SCHEMBL457104 | 0.81 | AR (0.40) | ARRIPK1GPR119EPAS1 | |
| SCHEMBL430865 | 0.81 | AR (0.40) | ARRIPK1GPR119EPAS1 | |
| SCHEMBL431625 | 0.81 | AR (0.40) | ARRIPK1GPR119EPAS1 | |
| SCHEMBL445865 | 0.81 | AR (0.40) | ARRIPK1GPR119EPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2678338-B1 | PYRAZOLO[1,5-A]PYRIDINES AS TRK INHIBITORS | NOVARTIS AG (CH) | 2015-09-09 | — | — | EP | disclosed |
| US-9102671-B2 | Compounds and compositions as TRK inhibitors | NOVARTIS AG (CH) | 2015-08-11 | — | — | US | disclosed |
| EP-2678338-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2014-01-01 | — | — | EP | disclosed |
| US-20130331397-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2013-12-12 | — | — | US | disclosed |
| WO-2012116217-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-08-30 | — | — | WO | disclosed |
| WO-2012116217-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-08-30 | — | — | WO | disclosed |
| WO-2012034095-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130331397-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | CNKSR1, BMP2K, RAF1 | AR 495/4885RIPK1 239/4885GPR119 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.